|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Study | Median dose of SBRT (gy) [range] | No. of fractions of SBRT (%) | Concurrent ADT at recurrence | Proportion of prostate targeted. | Use of rectal spacer |
| Leroy 2017 | 36 Gy  | 6 | 61% | Focal (<50%) = 13%Half gland = 4%Whole gland = 83% | N/A |
| Mbeutcha 2017 | 35 Gy | 5 | 56% | < half gland = 100% | N/A |
| Jereczek-Fossa 2018 | 30 [20-30] | 5 [2-10] | 25% | Prostate = 70%Whole gland + lesion = 30% | N/A |
| Paquier | 36 [25-36.25] | 5 (35%) – 6 (65%) | 34%  | < half gland = 32%Half gland = 18%Whole gland = 49% | 9% (balloon) |
| Fuller 2020 | 34 | 5 | 14% | Whole gland + extensions = 100% | N/A |
|  |  |  |  |  |  |

Table 3; Characteristics of SBRT utilised for included studies.

**Table 3**: Summary of salvage SBRT characteristics including, dosage, fractions and locations of therapy.